Evaluation of patients' real-world post-dispensing use and storage environments of tiotropium bromide Respimat (R) soft mist inhaler on its in vitro dose delivery and lung deposition

摘要

Background: Oral inhalation is the main drug delivery route for treating obstructive lung conditions. Thus, many inhaler devices with various design and pharmaceutical formulation have been introduced. The fine particle dose (FPD) and mass median aerodynamic diameter (MMAD <= 5 mu m) of the aerosol delivered dose (DD) dictate the therapeutically effective peripheral lung deposition. This study evaluated the in vitro aerosol emission performance of tiotropium bromide emitted from Spiriva (R) Respimat (R) soft mist inhalers (R) after living under patients' real-world, post-dispensing handling environments.